HTG Molecular Diagnostics Statistics
Share Statistics
HTG Molecular Diagnostics has 2.21M
shares outstanding. The number of shares has increased by 0%
in one year.
| Shares Outstanding | 2.21M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 17,086 |
| FTD / Avg. Volume | 6.73% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.16 and the forward
PE ratio is null.
HTG Molecular Diagnostics's PEG ratio is
0.01.
| PE Ratio | -0.16 |
| Forward PE | n/a |
| PS Ratio | 0.56 |
| Forward PS | n/a |
| PB Ratio | 0.66 |
| P/FCF Ratio | -0.19 |
| PEG Ratio | 0.01 |
Financial Ratio HistoryEnterprise Valuation
HTG Molecular Diagnostics has an Enterprise Value (EV) of -3.83M.
| EV / Sales | -0.6 |
| EV / EBITDA | 0.19 |
| EV / EBIT | 0.21 |
| EV / FCF | 0.21 |
Financial Position
The company has a current ratio of 1.89,
with a Debt / Equity ratio of 0.9.
| Current Ratio | 1.89 |
| Quick Ratio | 1.78 |
| Debt / Equity | 0.9 |
| Debt / EBITDA | -0.24 |
| Debt / FCF | -0.26 |
| Interest Coverage | -24.31 |
Financial Efficiency
Return on Equity is -400.51% and Return on Invested Capital is -203.8%.
| Return on Equity | -400.51% |
| Return on Assets | -121.47% |
| Return on Invested Capital | -203.8% |
| Revenue Per Employee | $120,117.36 |
| Profits Per Employee | $-407,442.94 |
| Employee Count | 53 |
| Asset Turnover | 0.36 |
| Inventory Turnover | 5.03 |
Taxes
| Income Tax | 10.84K |
| Effective Tax Rate | -0.05% |
Stock Price Statistics
The stock price has increased by 0% in the
last 52 weeks. The beta is 0.99, so HTG Molecular Diagnostics's
price volatility has been higher than the market average.
| Beta | 0.99 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 2.33 |
| 200-Day Moving Average | 4.75 |
| Relative Strength Index (RSI) | 18.67 |
| Average Volume (20 Days) | 253,915 |
Income Statement
In the last 12 months, HTG Molecular Diagnostics had revenue of 6.37M
and earned -21.59M
in profits. Earnings per share was -24.28.
| Revenue | 6.37M |
| Gross Profit | 1.79M |
| Operating Income | -20.83M |
| Net Income | -21.59M |
| EBITDA | -20.14M |
| EBIT | -20.73M |
| Earnings Per Share (EPS) | -24.28 |
Full Income StatementBalance Sheet
The company has 12.21M in cash and 4.83M in
debt, giving a net cash position of 7.38M.
| Cash & Cash Equivalents | 12.21M |
| Total Debt | 4.83M |
| Net Cash | 7.38M |
| Retained Earnings | -229.93M |
| Total Assets | 10.87M |
| Working Capital | 2.63M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -18.41M
and capital expenditures -23.04K, giving a free cash flow of -18.43M.
| Operating Cash Flow | -18.41M |
| Capital Expenditures | -23.04K |
| Free Cash Flow | -18.43M |
| FCF Per Share | -20.73 |
Full Cash Flow StatementMargins
Gross margin is 28.18%, with operating and profit margins of -327.19% and -339.2%.
| Gross Margin | 28.18% |
| Operating Margin | -327.19% |
| Pretax Margin | -339.03% |
| Profit Margin | -339.2% |
| EBITDA Margin | -316.35% |
| EBIT Margin | -327.19% |
| FCF Margin | -289.51% |
